Fig 1.
Raman spectra of PD patient urine and spent dialysate.
(A) Averaged, baselined, and vector normalized Raman spectra from 362 urine specimens obtained from patients receiving PD therapy for ESKD. (B) Averaged, baselined, and vector normalized Raman spectra from 395 spent PD dialysate specimens.
Fig 2.
PCA of PD patient urine and spent dialysate.
(A) PCA results for Raman spectra of 362 urine specimens obtained from patients receiving PD therapy for ESKD and 395 spent dialysate specimens. (B) Contributions of Raman shifts leading to separations among principal components.
Fig 3.
PCA of PD patient urine and urine from healthy individuals.
(A) PCA results for Raman spectra of 362 urine specimens obtained from patients receiving PD therapy for ESKD and 235 urine specimens from healthy individuals. (B) Contributions of Raman shifts leading to separations among principal components.
Table 1.
Pairwise comparisons using Tukey’s HSD procedure.
Fig 4.
DAPC of PD patient urine, spent dialysate, and urine from healthy individuals.
DAPC results for models made with 50 principal components. (A) 362 urine specimens obtained from patients receiving PD therapy for ESKD and 395 spent dialysate specimens. (B) 362 urine specimens obtained from patients receiving PD therapy for ESKD and 235 urine specimens from healthy individuals.
Table 2.
RametrixTM PRO results showing the ability to predict whether an unknown specimen from a PD patient is urine or spent dialysate.
Table 3.
RametrixTM PRO results showing the ability to predict whether an unknown urine specimen came from a PD patient or healthy human volunteer.